Page last updated: 2024-11-06

adenosine 5'-methylenediphosphate

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Adenosine 5'-methylenediphosphate (AMPPCP) is a non-hydrolyzable analog of ATP, meaning it cannot be broken down by enzymes. This makes it a useful tool for studying enzymatic reactions that involve ATP, as it can bind to the active site of an enzyme but not be broken down. AMPPCP is often used to study the mechanisms of ATP-dependent enzymes, such as kinases and ATPases. It can also be used to inhibit ATP-dependent processes in cells, such as muscle contraction and cell signaling. AMPPCP is synthesized by reacting adenosine 5'-monophosphate (AMP) with methylenediphosphonic acid.'

Cross-References

ID SourceID
PubMed CID92199
CHEMBL ID583969
CHEBI ID40730
SCHEMBL ID4314227

Synonyms (61)

Synonym
nsc-614641
3768-14-7
MLS000028681
alpha,beta-methyleneadenosine 5'-diphosphate
smr000058652
phosphomethylphosphonic acid adenosyl ester
AP2 ,
DB03148
alpha,beta-methyleneadenosine-5'-diphosphate
CHEBI:40730 ,
NCGC00163326-01
adenosine 5'-(hydrogen (phosphonomethyl)phosphonate)
5'-o-[hydroxy(phosphonomethyl)phosphoryl]adenosine
adenosine 5'-methylenediphosphate
adenosine, 5'-(trihydrogen methylenebis(phosphonate))
nsc 614641
einecs 223-194-0
[({[(2r,3s,4r,5r)-5-(6-amino-9h-purin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy}(hydroxy)phosphoryl)methyl]phosphonic acid
cid_92199
adp, alpha beta-me
alpha, beta-methyleneadenosine 5 -diphosphate
bdbm18136
104835-70-3
CHEMBL583969
SCHEMBL4314227
alpha,beta-methylene adenosine 5'-diphosphate
[[(2r,3s,4r,5r)-5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]methylphosphonic acid
adenosine 5'-(alpha,beta-methylene)diphosphoric acid
0t2a5439oe ,
unii-0t2a5439oe
amp-cp
ampcp
alpha,beta-methyleneadenosine 5'-diphosphate sodium salt
[alphabetach2]adp
alpha,beta-methyleneadenosine 5'-diphosphate (alphabetameadp)
gtpl5092
alphabeta-methyleneadp
adenosine, 5'-(trihydrogen methylenediphosphonate)
methadp
5'-adenylyl methylenephosphonate
.alpha.,.beta.-methylene adenosine 5'-diphosphate
.alpha.,.beta.-methylene-adp
.alpha.,.beta.-methylene-5'-adp
adenosine .alpha.,.beta.-methylenediphosphate
.alpha.,.beta.-methylene adenosine diphosphate
adenosine, 5'-(hydrogen p-(phosphonomethyl)phosphonate)
adenosine, 5'-(hydrogen (phosphonomethyl)phosphonate)
adenosine 5'-(.alpha.,.beta.-methylene)diphosphate
J-001270
CS-0046156
HY-112502
AKOS030573816
((((2r,3s,4r,5r)-5-(6-amino-9h-purin-9-yl)-3,4-dihydroxytetrahydrofuran-2-yl)methoxy)(hydroxy)phosphoryl)methylphosphonic acid
5'-o-[(s)-hydroxy(phosphonomethyl)phosphoryl]adenosine
5'-o-[(r)-hydroxy(phosphonomethyl)phosphoryl]adenosine
adenosine 5'-(alpha,beta-methylene) diphosphate
Q27074395
methadp (adenosine 5'-(alpha,beta-methylene)diphosphate)
adenosine 5'-(|a,|a-methylene)diphosphate
adenosine 5'-(,-methylene)diphosphate
alpha , beta -methyleneadenosine 5'-diphosphate sodium salt
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
nucleoside diphosphate analogue
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (17)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, JmjC domain-containing histone demethylation protein 3AHomo sapiens (human)Potency79.43280.631035.7641100.0000AID504339
acid sphingomyelinaseHomo sapiens (human)Potency63.095714.125424.061339.8107AID504937
TDP1 proteinHomo sapiens (human)Potency10.80690.000811.382244.6684AID686978; AID686979
IDH1Homo sapiens (human)Potency25.92900.005210.865235.4813AID686970
urokinase-type plasminogen activator precursorMus musculus (house mouse)Potency5.01190.15855.287912.5893AID540303
plasminogen precursorMus musculus (house mouse)Potency5.01190.15855.287912.5893AID540303
urokinase plasminogen activator surface receptor precursorMus musculus (house mouse)Potency5.01190.15855.287912.5893AID540303
Inositol monophosphatase 1Rattus norvegicus (Norway rat)Potency25.11891.000010.475628.1838AID1457
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Phospholipase C, gamma 1Homo sapiens (human)IC50 (µMol)2.19801.21203.16626.3720AID743329
5'-nucleotidaseRattus norvegicus (Norway rat)Ki0.41130.00090.25600.8700AID1593548; AID1605333; AID1692594
5'-nucleotidaseHomo sapiens (human)IC50 (µMol)5.75360.05002.24118.2000AID1408359; AID1408360; AID1408361; AID1674319; AID1692589; AID1692590; AID1692592; AID1692593; AID1693837; AID1724307; AID1889898
5'-nucleotidaseHomo sapiens (human)Ki0.16560.08840.16560.5100AID1605334; AID1605335; AID1606468; AID1674319; AID1692595; AID1819262; AID1889905
Ectonucleotide pyrophosphatase/phosphodiesterase family member 1Homo sapiens (human)Ki16.87600.52003.93508.1900AID1415776; AID1415777; AID1415778; AID1415779; AID1415784
Ectonucleoside triphosphate diphosphohydrolase 1Mus musculus (house mouse)IC50 (µMol)100.00000.50001.03001.5600AID1693839
Glycine--tRNA ligaseBombyx mori (domestic silkworm)Ki60.00000.80000.80000.8000AID1797699
5'-nucleotidaseMus musculus (house mouse)IC50 (µMol)4.63000.04003.10004.6300AID1693838; AID1889899
Ectonucleotide pyrophosphatase/phosphodiesterase family member 1 Rattus norvegicus (Norway rat)Ki9.60002.20005.90009.6000AID1415786
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (35)

Processvia Protein(s)Taxonomy
DNA metabolic process5'-nucleotidaseHomo sapiens (human)
leukocyte cell-cell adhesion5'-nucleotidaseHomo sapiens (human)
response to inorganic substance5'-nucleotidaseHomo sapiens (human)
response to ATP5'-nucleotidaseHomo sapiens (human)
ADP catabolic process5'-nucleotidaseHomo sapiens (human)
ATP metabolic process5'-nucleotidaseHomo sapiens (human)
adenosine biosynthetic process5'-nucleotidaseHomo sapiens (human)
negative regulation of inflammatory response5'-nucleotidaseHomo sapiens (human)
calcium ion homeostasis5'-nucleotidaseHomo sapiens (human)
inhibition of non-skeletal tissue mineralization5'-nucleotidaseHomo sapiens (human)
AMP catabolic process5'-nucleotidaseHomo sapiens (human)
generation of precursor metabolites and energyEctonucleotide pyrophosphatase/phosphodiesterase family member 1Homo sapiens (human)
phosphate-containing compound metabolic processEctonucleotide pyrophosphatase/phosphodiesterase family member 1Homo sapiens (human)
immune responseEctonucleotide pyrophosphatase/phosphodiesterase family member 1Homo sapiens (human)
nucleoside triphosphate catabolic processEctonucleotide pyrophosphatase/phosphodiesterase family member 1Homo sapiens (human)
response to inorganic substanceEctonucleotide pyrophosphatase/phosphodiesterase family member 1Homo sapiens (human)
gene expressionEctonucleotide pyrophosphatase/phosphodiesterase family member 1Homo sapiens (human)
vesicle-mediated transportEctonucleotide pyrophosphatase/phosphodiesterase family member 1Homo sapiens (human)
bone mineralizationEctonucleotide pyrophosphatase/phosphodiesterase family member 1Homo sapiens (human)
negative regulation of cell growthEctonucleotide pyrophosphatase/phosphodiesterase family member 1Homo sapiens (human)
melanocyte differentiationEctonucleotide pyrophosphatase/phosphodiesterase family member 1Homo sapiens (human)
regulation of bone mineralizationEctonucleotide pyrophosphatase/phosphodiesterase family member 1Homo sapiens (human)
negative regulation of bone mineralizationEctonucleotide pyrophosphatase/phosphodiesterase family member 1Homo sapiens (human)
inorganic diphosphate transportEctonucleotide pyrophosphatase/phosphodiesterase family member 1Homo sapiens (human)
intracellular phosphate ion homeostasisEctonucleotide pyrophosphatase/phosphodiesterase family member 1Homo sapiens (human)
sequestering of triglycerideEctonucleotide pyrophosphatase/phosphodiesterase family member 1Homo sapiens (human)
negative regulation of protein autophosphorylationEctonucleotide pyrophosphatase/phosphodiesterase family member 1Homo sapiens (human)
cellular response to insulin stimulusEctonucleotide pyrophosphatase/phosphodiesterase family member 1Homo sapiens (human)
response to ATPEctonucleotide pyrophosphatase/phosphodiesterase family member 1Homo sapiens (human)
negative regulation of fat cell differentiationEctonucleotide pyrophosphatase/phosphodiesterase family member 1Homo sapiens (human)
negative regulation of glycogen biosynthetic processEctonucleotide pyrophosphatase/phosphodiesterase family member 1Homo sapiens (human)
ATP metabolic processEctonucleotide pyrophosphatase/phosphodiesterase family member 1Homo sapiens (human)
negative regulation of glucose importEctonucleotide pyrophosphatase/phosphodiesterase family member 1Homo sapiens (human)
negative regulation of insulin receptor signaling pathwayEctonucleotide pyrophosphatase/phosphodiesterase family member 1Homo sapiens (human)
3'-phosphoadenosine 5'-phosphosulfate metabolic processEctonucleotide pyrophosphatase/phosphodiesterase family member 1Homo sapiens (human)
phosphate ion homeostasisEctonucleotide pyrophosphatase/phosphodiesterase family member 1Homo sapiens (human)
nucleic acid metabolic processEctonucleotide pyrophosphatase/phosphodiesterase family member 1Homo sapiens (human)
negative regulation of hh target transcription factor activityEctonucleotide pyrophosphatase/phosphodiesterase family member 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (28)

Processvia Protein(s)Taxonomy
nucleotide binding5'-nucleotidaseHomo sapiens (human)
5'-deoxynucleotidase activity5'-nucleotidaseHomo sapiens (human)
protein binding5'-nucleotidaseHomo sapiens (human)
5'-nucleotidase activity5'-nucleotidaseHomo sapiens (human)
zinc ion binding5'-nucleotidaseHomo sapiens (human)
identical protein binding5'-nucleotidaseHomo sapiens (human)
thymidylate 5'-phosphatase activity5'-nucleotidaseHomo sapiens (human)
IMP 5'-nucleotidase activity5'-nucleotidaseHomo sapiens (human)
GMP 5'-nucleotidase activity5'-nucleotidaseHomo sapiens (human)
XMP 5'-nucleosidase activity5'-nucleotidaseHomo sapiens (human)
nucleic acid bindingEctonucleotide pyrophosphatase/phosphodiesterase family member 1Homo sapiens (human)
3',5'-cyclic-AMP phosphodiesterase activityEctonucleotide pyrophosphatase/phosphodiesterase family member 1Homo sapiens (human)
exonuclease activityEctonucleotide pyrophosphatase/phosphodiesterase family member 1Homo sapiens (human)
phosphodiesterase I activityEctonucleotide pyrophosphatase/phosphodiesterase family member 1Homo sapiens (human)
dinucleotide phosphatase activityEctonucleotide pyrophosphatase/phosphodiesterase family member 1Homo sapiens (human)
scavenger receptor activityEctonucleotide pyrophosphatase/phosphodiesterase family member 1Homo sapiens (human)
insulin receptor bindingEctonucleotide pyrophosphatase/phosphodiesterase family member 1Homo sapiens (human)
calcium ion bindingEctonucleotide pyrophosphatase/phosphodiesterase family member 1Homo sapiens (human)
protein bindingEctonucleotide pyrophosphatase/phosphodiesterase family member 1Homo sapiens (human)
ATP bindingEctonucleotide pyrophosphatase/phosphodiesterase family member 1Homo sapiens (human)
zinc ion bindingEctonucleotide pyrophosphatase/phosphodiesterase family member 1Homo sapiens (human)
phosphatase activityEctonucleotide pyrophosphatase/phosphodiesterase family member 1Homo sapiens (human)
polysaccharide bindingEctonucleotide pyrophosphatase/phosphodiesterase family member 1Homo sapiens (human)
GTP diphosphatase activityEctonucleotide pyrophosphatase/phosphodiesterase family member 1Homo sapiens (human)
UTP diphosphatase activityEctonucleotide pyrophosphatase/phosphodiesterase family member 1Homo sapiens (human)
protein homodimerization activityEctonucleotide pyrophosphatase/phosphodiesterase family member 1Homo sapiens (human)
nucleoside triphosphate diphosphatase activityEctonucleotide pyrophosphatase/phosphodiesterase family member 1Homo sapiens (human)
ATP diphosphatase activityEctonucleotide pyrophosphatase/phosphodiesterase family member 1Homo sapiens (human)
3'-phosphoadenosine 5'-phosphosulfate bindingEctonucleotide pyrophosphatase/phosphodiesterase family member 1Homo sapiens (human)
cyclic-GMP-AMP hydrolase activityEctonucleotide pyrophosphatase/phosphodiesterase family member 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (10)

Processvia Protein(s)Taxonomy
plasma membrane5'-nucleotidaseHomo sapiens (human)
nucleoplasm5'-nucleotidaseHomo sapiens (human)
cytosol5'-nucleotidaseHomo sapiens (human)
plasma membrane5'-nucleotidaseHomo sapiens (human)
external side of plasma membrane5'-nucleotidaseHomo sapiens (human)
cell surface5'-nucleotidaseHomo sapiens (human)
membrane5'-nucleotidaseHomo sapiens (human)
extracellular exosome5'-nucleotidaseHomo sapiens (human)
plasma membraneEctonucleotide pyrophosphatase/phosphodiesterase family member 1Homo sapiens (human)
extracellular spaceEctonucleotide pyrophosphatase/phosphodiesterase family member 1Homo sapiens (human)
lysosomal membraneEctonucleotide pyrophosphatase/phosphodiesterase family member 1Homo sapiens (human)
plasma membraneEctonucleotide pyrophosphatase/phosphodiesterase family member 1Homo sapiens (human)
cell surfaceEctonucleotide pyrophosphatase/phosphodiesterase family member 1Homo sapiens (human)
membraneEctonucleotide pyrophosphatase/phosphodiesterase family member 1Homo sapiens (human)
basolateral plasma membraneEctonucleotide pyrophosphatase/phosphodiesterase family member 1Homo sapiens (human)
cell surfaceEctonucleotide pyrophosphatase/phosphodiesterase family member 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (54)

Assay IDTitleYearJournalArticle
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID1693837Inhibition of human CD732021Bioorganic & medicinal chemistry letters, 02-15, Volume: 34Discovery of natural product ellagic acid as a potent CD73 and CD39 dual inhibitor.
AID1605341Activation of recombinant human P2Y12 receptor expressed in CHOK1 cells assessed as stimulation of calcium mobilization at 10 uM incubated for 90 mins by luminescence based assay2020Journal of medicinal chemistry, 03-26, Volume: 63, Issue:6
2-Substituted α,β-Methylene-ADP Derivatives: Potent Competitive Ecto-5'-nucleotidase (CD73) Inhibitors with Variable Binding Modes.
AID1819265Inhibition of 5'-Nucleotidase activity in human HN-SCC cells assessed as reduction in tumor CD73 catalytic activity incubated for 45 mins in presence of Pb(NO3)2 by H and E staining based assay2022Journal of medicinal chemistry, 02-10, Volume: 65, Issue:3
Structure-Activity Relationship of 3-Methylcytidine-5'-α,β-methylenediphosphates as CD73 Inhibitors.
AID1606468Inhibition of human CD732020Journal of medicinal chemistry, 04-23, Volume: 63, Issue:8
Discovery of Potent and Selective Non-Nucleotide Small Molecule Inhibitors of CD73.
AID440574Binding affinity to Mycobacterium tuberculosis adenosine-5'-phosphosulfate reductase assessed as S-sulfocysteine formation at pH 5.5 by single turnover method in absence of thioredoxin2009Journal of medicinal chemistry, Sep-10, Volume: 52, Issue:17
Identification of critical ligand binding determinants in Mycobacterium tuberculosis adenosine-5'-phosphosulfate reductase.
AID1693839Inhibition of mouse CD392021Bioorganic & medicinal chemistry letters, 02-15, Volume: 34Discovery of natural product ellagic acid as a potent CD73 and CD39 dual inhibitor.
AID1692592Inhibition of human C-terminal His6-tagged CD73 expressed in HEK293F cells using [15N]5-AMP as substrate preincubated for 1 hr followed by substrate addition and measured after 8 mins by MS/MS assay2020Journal of medicinal chemistry, 11-25, Volume: 63, Issue:22
Targeting Metabolism of Extracellular Nucleotides via Inhibition of Ectonucleotidases CD73 and CD39.
AID1605343Metabolic stability in rat liver microsomes assessed as compound degradation at 200 uM after 30 mins in presence of NADPH regenerative system at 37 degC by LC-MS analysis2020Journal of medicinal chemistry, 03-26, Volume: 63, Issue:6
2-Substituted α,β-Methylene-ADP Derivatives: Potent Competitive Ecto-5'-nucleotidase (CD73) Inhibitors with Variable Binding Modes.
AID1889905Inhibition of CD73 (unknown origin)2022Bioorganic & medicinal chemistry, 04-01, Volume: 59Discovery and optimization of betulinic acid derivatives as novel potent CD73 inhibitors.
AID1605342Metabolic stability in human blood plasma assessed as compound degradation at 200 uM incubated for 5 hrs at 37 degC by LC-MS analysis2020Journal of medicinal chemistry, 03-26, Volume: 63, Issue:6
2-Substituted α,β-Methylene-ADP Derivatives: Potent Competitive Ecto-5'-nucleotidase (CD73) Inhibitors with Variable Binding Modes.
AID1692594Inhibition of rat CD73 expressed in baculovirus infected insect cells using AMP substrate by capillary electrophoresis assay2020Journal of medicinal chemistry, 11-25, Volume: 63, Issue:22
Targeting Metabolism of Extracellular Nucleotides via Inhibition of Ectonucleotidases CD73 and CD39.
AID1408359Inhibition of recombinant CD73 (27 to 549 residues) (unknown origin) expressed in baculovirus infected Sf9 insect cells assessed as reduction in conversion of AMP to adenosine incubated for 1 min followed by AMP addition measured after 3.5 mins by malachi2018European journal of medicinal chemistry, Sep-05, Volume: 157CD73 inhibition by purine cytotoxic nucleoside analogue-based diphosphonates.
AID1692589Inhibition of recombinant human CD73 using AMP as substrate incubated for 90 mins by malachite green colorimetric assay2020Journal of medicinal chemistry, 11-25, Volume: 63, Issue:22
Targeting Metabolism of Extracellular Nucleotides via Inhibition of Ectonucleotidases CD73 and CD39.
AID1605340Activation of recombinant human P2Y1 receptor expressed in human 1321N1 cells assessed as stimulation of calcium mobilization at 10 uM by fluorescence based assay2020Journal of medicinal chemistry, 03-26, Volume: 63, Issue:6
2-Substituted α,β-Methylene-ADP Derivatives: Potent Competitive Ecto-5'-nucleotidase (CD73) Inhibitors with Variable Binding Modes.
AID1889898Inhibition of human CD73 assessed as reduction in inorganic phosphate release upon substrate hydrolysis using AMP/ATP as substrate incubated for 1 hr followed by substrate addition and measured after 2 hrs by malachite green reagent based colorimetric ass2022Bioorganic & medicinal chemistry, 04-01, Volume: 59Discovery and optimization of betulinic acid derivatives as novel potent CD73 inhibitors.
AID1593549Inhibition of recombinant rat C-terminal His-tagged soluble form of CD73 expressed in baculovirus infected Sf9 insect cells at 1 uM using [2,8-3H]AMP as substrate measured after 25 mins by scintillation counting method relative to control2019Journal of medicinal chemistry, 04-11, Volume: 62, Issue:7
Structure-Activity Relationship of Purine and Pyrimidine Nucleotides as Ecto-5'-Nucleotidase (CD73) Inhibitors.
AID1408361Inhibition of CD73 in human NCI-H292 cells assessed as reduction in conversion of AMP to adenosine incubated for 30 mins by malachite green reagent based assay2018European journal of medicinal chemistry, Sep-05, Volume: 157CD73 inhibition by purine cytotoxic nucleoside analogue-based diphosphonates.
AID1693838Inhibition of mouse CD732021Bioorganic & medicinal chemistry letters, 02-15, Volume: 34Discovery of natural product ellagic acid as a potent CD73 and CD39 dual inhibitor.
AID1593548Inhibition of recombinant rat C-terminal His-tagged soluble form of CD73 expressed in baculovirus infected Sf9 insect cells using [2,8-3H]AMP as substrate measured after 25 mins by scintillation counting method2019Journal of medicinal chemistry, 04-11, Volume: 62, Issue:7
Structure-Activity Relationship of Purine and Pyrimidine Nucleotides as Ecto-5'-Nucleotidase (CD73) Inhibitors.
AID1605334Inhibition of purified recombinant soluble human CD73 expressed in Sf9 cells [3H]AMP as substrate incubated for 25 mins by scintillation counting method2020Journal of medicinal chemistry, 03-26, Volume: 63, Issue:6
2-Substituted α,β-Methylene-ADP Derivatives: Potent Competitive Ecto-5'-nucleotidase (CD73) Inhibitors with Variable Binding Modes.
AID1724308Inhibition of CD73 in human NCI-H1568 cells assessed as reduction in AMP-induced ADO expression preincubated for 15 mins followed by AMP addition and measured after 1 hr by LC-MS/MS analysis
AID1724307Inhibition of human C-terminal His6-tagged CD73 expressed in CHO cells preincubated for 15 mins followed by AMP addition and measured after 10 mins by malachite green reagent based assay
AID1819266Inhibition of 5'-Nucleotidase activity in human tonsils assessed as reduction in CD73 catalytic activity in tonsils incubated for 45 mins in presence of Pb(NO3)2 by H and E staining based assay2022Journal of medicinal chemistry, 02-10, Volume: 65, Issue:3
Structure-Activity Relationship of 3-Methylcytidine-5'-α,β-methylenediphosphates as CD73 Inhibitors.
AID1889899Inhibition of mouse CD73 assessed as reduction in inorganic phosphate release upon substrate hydrolysis using AMP/ATP as substrate incubated for 1 hr followed by substrate addition and measured after 2 hrs by malachite green reagent based colorimetric ass2022Bioorganic & medicinal chemistry, 04-01, Volume: 59Discovery and optimization of betulinic acid derivatives as novel potent CD73 inhibitors.
AID1415776Competitive-inhibition of recombinant human N-terminal His-tagged soluble NPP1 (Val191 to Leu591 residues) expressed in mouse NSO cells using ATP as substrate by capillary electrophoresis method2017MedChemComm, May-01, Volume: 8, Issue:5
Nucleotide pyrophosphatase/phosphodiesterase 1 (NPP1) and its inhibitors.
AID1415779Competitive-inhibition of recombinant human N-terminal His-tagged soluble NPP1 (Val191 to Leu591 residues) expressed in mouse NSO cells using p-Nph-5'-AMP as substrate after 30 mins by capillary electrophoresis method2017MedChemComm, May-01, Volume: 8, Issue:5
Nucleotide pyrophosphatase/phosphodiesterase 1 (NPP1) and its inhibitors.
AID1692590Inhibition of recombinant human CD73 using AMP as substrate incubated for 120 mins by CellTiter-Glo assay2020Journal of medicinal chemistry, 11-25, Volume: 63, Issue:22
Targeting Metabolism of Extracellular Nucleotides via Inhibition of Ectonucleotidases CD73 and CD39.
AID1692595Inhibition of CD73 in human melanoma 1539 cells using AMP substrate by capillary electrophoresis assay2020Journal of medicinal chemistry, 11-25, Volume: 63, Issue:22
Targeting Metabolism of Extracellular Nucleotides via Inhibition of Ectonucleotidases CD73 and CD39.
AID1415784Competitive-inhibition of recombinant human NPP1 expressed in HEK293 cell membranes using p-Nph-5'-TMP as substrate pretreated for 10 mins followed by substrate addition and measured after 60 mins by capillary electrophoresis method2017MedChemComm, May-01, Volume: 8, Issue:5
Nucleotide pyrophosphatase/phosphodiesterase 1 (NPP1) and its inhibitors.
AID1819262Inhibition of human recombinant soluble CD73 assessed as inhibition constant by radiometric assay2022Journal of medicinal chemistry, 02-10, Volume: 65, Issue:3
Structure-Activity Relationship of 3-Methylcytidine-5'-α,β-methylenediphosphates as CD73 Inhibitors.
AID1408360Inhibition of CD73 in human MDA-MB-231 cells assessed as reduction in conversion of AMP to adenosine incubated for 30 mins by malachite green reagent based assay2018European journal of medicinal chemistry, Sep-05, Volume: 157CD73 inhibition by purine cytotoxic nucleoside analogue-based diphosphonates.
AID1889901Induction of anti-CD3/CD28 antibodies-stimulated CD4-positive Th cell activation in C57BL/6J mouse assessed as reversal of AMP/EHNA-inhibited IFN-gamma production at 10 uM preincubated for 15 mins followed by AMP/EHNA addition and measured after 96 hrs by2022Bioorganic & medicinal chemistry, 04-01, Volume: 59Discovery and optimization of betulinic acid derivatives as novel potent CD73 inhibitors.
AID1415786Mixed-inhibition of Wistar rat NPP1 using p-Nph-5'-TMP as substrate measured after 5 mins by UPLC method2017MedChemComm, May-01, Volume: 8, Issue:5
Nucleotide pyrophosphatase/phosphodiesterase 1 (NPP1) and its inhibitors.
AID1605335Inhibition of native CD73 in human MDA-MB-231 cell membrane preparations [3H]AMP as substrate incubated for 25 mins by scintillation counting method2020Journal of medicinal chemistry, 03-26, Volume: 63, Issue:6
2-Substituted α,β-Methylene-ADP Derivatives: Potent Competitive Ecto-5'-nucleotidase (CD73) Inhibitors with Variable Binding Modes.
AID1415777Competitive-inhibition of recombinant human N-terminal His-tagged soluble NPP1 (Val191 to Leu591 residues) expressed in mouse NSO cells using ATP as substrate after 30 mins by capillary electrophoresis method2017MedChemComm, May-01, Volume: 8, Issue:5
Nucleotide pyrophosphatase/phosphodiesterase 1 (NPP1) and its inhibitors.
AID1415778Competitive-inhibition of recombinant human N-terminal His-tagged soluble NPP1 (Val191 to Leu591 residues) expressed in mouse NSO cells using p-Nph-5'-TMP as substrate after 15 mins by capillary electrophoresis method2017MedChemComm, May-01, Volume: 8, Issue:5
Nucleotide pyrophosphatase/phosphodiesterase 1 (NPP1) and its inhibitors.
AID1674319Inhibition of human CD73 using AMP as substrate by Malachite green phosphate reagent-based assay2020Journal of medicinal chemistry, 10-22, Volume: 63, Issue:20
Discovery of AB680: A Potent and Selective Inhibitor of CD73.
AID1692593Inhibition of human CD73 expressed in CHO cells using AMP as substrate preincubated for 10 mins followed by substrate addition and measured every minute for 10 to 20 mins by PNP coupled enzyme assay2020Journal of medicinal chemistry, 11-25, Volume: 63, Issue:22
Targeting Metabolism of Extracellular Nucleotides via Inhibition of Ectonucleotidases CD73 and CD39.
AID1605333Inhibition of purified recombinant soluble rat CD73 expressed in Sf9 cells [3H]AMP as substrate incubated for 25 mins by scintillation counting method2020Journal of medicinal chemistry, 03-26, Volume: 63, Issue:6
2-Substituted α,β-Methylene-ADP Derivatives: Potent Competitive Ecto-5'-nucleotidase (CD73) Inhibitors with Variable Binding Modes.
AID1593546Inhibition of CD73 in human tonsils at 100 nM using AMP as substrate preincubated for 30 mins followed by substrate addition and measured after 45 mins by lead nitrate-based histochemical analysis2019Journal of medicinal chemistry, 04-11, Volume: 62, Issue:7
Structure-Activity Relationship of Purine and Pyrimidine Nucleotides as Ecto-5'-Nucleotidase (CD73) Inhibitors.
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347154Primary screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1797699In Vitro Enzyme Activity Assay from Article 10.1021/bi030031h: \\Thermodynamic characterization of the binding of nucleotides to glycyl-tRNA synthetase.\\2003Biochemistry, May-13, Volume: 42, Issue:18
Thermodynamic characterization of the binding of nucleotides to glycyl-tRNA synthetase.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (181)

TimeframeStudies, This Drug (%)All Drugs %
pre-199042 (23.20)18.7374
1990's56 (30.94)18.2507
2000's39 (21.55)29.6817
2010's29 (16.02)24.3611
2020's15 (8.29)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 9.37

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index9.37 (24.57)
Research Supply Index5.21 (2.92)
Research Growth Index4.58 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (9.37)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews2 (1.10%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other180 (98.90%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]